DOCSLIB.ORG

Effects of Sustained (±)Pindolol Administration on Serotonin Neurotransmission in Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Sustained (±)Pindolol Administration on Serotonin Neurotransmission in Rats Research Paper Article de recherche Return to September 5, 2000 Table of Contents Effects of sustained (±)pindolol administration on serotonin neurotransmission in rats Nasser Haddjeri, PhD; Pierre Blier, MD, PhD Haddjeri — Centre de recherche en sciences neurologiques, Université de Montréal, Montreal, Que.; Blier — Department of Psychiatry, Brain Institute, University of Florida, Gainesville, Fla. β Objective: Given reports that (±)pindolol, a -adrenergic–5-HT1A/1B receptor antagonist, accelerates the onset of the therapeutic effect of certain antidepressant drugs in major depression, the aim of this study was to assess the effect of sustained (±)pindolol administration on the sensitivity of pre- and postsynaptic 5-HT1A receptors, terminal 5-HT1B autoreceptors and on overall 5-HT neurotransmission. Design: Prospective animal study. Animals: Sprague-Dawley rats. Outcome measures: Modifications of the sen- sitivity of somatodendritic and postsynaptic 5-HT1A receptors using in vivo electrophysiological paradigms in animals treated with vehicle or (±)pindolol (20 mg/kg/day, subcutaneously) through osmotic minipumps for 2 weeks. Results: (±)Pindolol attenuated the suppressant effect of the 5-HT autoreceptor agonist lysergic acid diethylamide (LSD) on the firing activity of 5-HT neurons, suggesting that (±)pindolol antago- nized somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus. However, following a 2-day washout period, the suppressant effect of LSD was still attenuated, indicating rather a desensitization of 5- HT1A autoreceptors had occurred. In the CA3 region of the dorsal hippocampus, (±)pindolol treatment did not modify the responsiveness of postsynaptic 5-HT1A receptors to microiontophoretic applications of 5- HT. Moreover, such a treatment modified neither the effectiveness of the electrical stimulation of 5-HT fibers nor the function of terminal 5-HT autoreceptors. Finally, the administration of the selective 5-HT1A receptor antagonist WAY 100635 (100 µg/kg, intravenously) did not increase the firing activity of dorsal hippocampus CA3 pyramidal neurons in rats treated with (±)pindolol, thus failing to reveal the enhanced tonic activation of postsynaptic 5-HT1A receptors associated with major classes of antidepressant treat- ments. Conclusion: Prolonged administration of (±)pindolol by itself is not sufficient to enhance overall 5-HT neurotransmission; pindolol should therefore not be endowed with intrinsic antidepressant activity. Although pindolol is capable of antagonizing the 5-HT1A autoreceptor upon the initiation of a 5-HT reup- take-blocker treatment, it also induces a desensitization of this 5-HT1A autoreceptor, which could explain why patients do not relapse upon its discontinuation when they continue taking a 5-HT reuptake blocker. Objectif : Des études cliniques ont récemment démontré que le (±)pindolol, un antagoniste des récep- β teurs -adrenergic/5-HT1A/1B, accélérait la réponse thérapeutique de certains médicaments antidépresseurs chez des patients atteints de dépression majeure. Le but de la présente étude était d’évaluer les effets d’une administration prolongée de (±)pindolol sur la sensibilité des récepteurs pré et postsynaptiques 5-HT1A, Correspondence to: Dr. Pierre Blier, Department of Psychiatry, Brain Institute, University of Florida, PO Box 100256, Gainesville FL 32610; fax 352 392-2579 Medical subject headings: antidepressant agents; depression; lysergic acid diethylamide; pindolol; rats, Sprague-Dawley; receptors, serotonin J Psychiatry Neurosci 2000;25(4):378-88. Submitted July 19, 1999 Accepted Apr. 5, 2000 © 2000 Canadian Medical Association 378 Revue de psychiatrie et de neuroscience Vol. 25, no 4, 2000 (±)Pindolol and 5-HT neurotransmission celle des autorécepteurs 5-HT1B terminaux ainsi que sur la neurotransmission serotoninèrgique du cerveau de rat. Conception : Étude prospective sur des animaux. Animaux : Rats males Sprague-Dawley. Mesures des résul- tats : Modifications de la sensibilité des récepteurs 5-HT1A somatodendritiques et postsynaptiques en utilisant des méthodes électrophysiologiques in vivo chez des rats contrôles et traités par le (±)pindolol pour une période de 2 semaines à une dose de 20 mg/kg/jour (s.c.) en utilisant des mini-pompes osmotiques. Résultats : Un traite- ment à long-terme avec du (±)pindolol a atténué l’effet inhibiteurs du LSD, un agoniste des autorecepteurs 5-HT, sur la fréquence de décharge des neurones 5-HT du noyau du raphé dorsal, ce qui suggère un antagonisme des autorécepteurs somatodendritiques 5-HT1A. Toutefois, après une période d’écimination de 2 jours, l’effet inhibi- teur du LSD était toujours atténué, ce qui indique plutôt une désensibilisation des autorécepteurs 5-HT1A. Dans la région CA3 de l’hippocampe dorsal, des applications microiontophorétiques de 5-HT ont révelé que le traite- ment au (±)pindolol ne modifiait pas les réponses des récepteurs postsynaptiques 5-HT1A. De plus, un tel traite- ment ne changeait ni l’efficacité des stimulations électriques des fibres 5-HT ni la fonction autorecepteurs 5-HT terminaux. Finalement, l’administration intraveineuse du WAY 100635 (100 µg/kg), un antagoniste sélectif des récepteurs 5-HT1A, n’augmentait pas la fréquence de décharge des neurones des neurones pyramidaux CA3 de l’hippocampe dorsal chez des traités par le (±)pindolol, ne dévoilant pas une augmentation de l’activation tonique des récepteurs postsynaptiques 5-HT1A, comme c’est le cas pour les traitements antidépresseurs. Conclusion : Ces résultats indiquent qu’une administration prolongée de (±)pindolol en soi n’est pas suffisante pour augmenter la neurotransmission 5-HT et que cet agent serait dépourvu d’activité antidépressive. Bien que le pindolol soit capable d’antagoniser les autorécepteurs 5-HT1A dès le début de l’administration soutenue d’un bloqueur de la recapture de 5-HT, il produit également leur désensibilisation. Ceci expliquerait le fait que les patients ne Introduction SSRIs on extracellular 5-HT concentration by prevent- ing the activation of somatodendritic 5-HT1A autore- Although the pathophysiology of major depression has ceptors.14,15 Paradoxically, however, the active enan- not been elucidated, there is a growing body of evi- tiomer, (–)pindolol, possesses some partial agonist 16 dence that supports the involvement of the serotonergic activity at human 5-HT1A receptors, and it has been (5-HT) system in the therapeutic effect of antidepres- shown that its intravenous administration can sant treatments.1,2 Various classes of antidepressant decrease the firing activity of dorsal raphe 5-HT neu- treatments enhance 5-HT neurotransmission with a rons in freely-moving cats and anesthetised rats.17–19 time course that is consistent with their delayed thera- These results appear incompatible with a potentiation peutic effect. This would be mediated via different of extracellular 5-HT levels in postsynaptic structures mechanisms such as postsynaptic sensitization to 5-HT, resulting from 5-HT1A autoreceptor blockade by pin- desensitization of the somatodendritic or terminal 5-HT dolol when given in combination with SSRIs.14 α autoreceptors, or both, or a desensitization of 2-adren- Nevertheless, a biphasic effect of pindolol on the firing ergic heteroreceptors located on 5-HT terminals.1,3 activity of 5-HT neurons has been reported recently. A novel strategy to accelerate the antidepressant At low doses, (±)pindolol acts as a somatodendritic 5- response of medications acting on 5-HT neurons is to HT1A autoreceptor antagonist, but at a higher dose, it combine the arylalkylamine (±)pindolol, a β-adrener- decreases the firing rate of 5-HT neurons, in part by gic–5-HT1A/1B receptor antagonist, with a selective sero- attenuating the tonic excitatory input from noradren- tonin reuptake inhibitor (SSRI), a monoamine oxidase ergic neurons to 5-HT neurons.19 inhibitor (MAOI) or a 5-HT1A receptor agonist from the To mimic as much as possible the clinical condition in beginning of a treatment to obtain a more rapid onset which pindolol has been given 3 times daily in double- of antidepressant action.4 Although negative results blind trials, we treated rats with (±)pindolol for 2 weeks have been reported by one group,5,6 there are now 7 and used in vivo electrophysiological paradigms in the placebo-controlled studies showing that this approach rat dorsal raphe and dorsal hippocampus to assess the can result in a rapid onset of action and, in some cases, effect of sustained treatment with a constant infusion of a greater efficacy in treating major depression.7–13 (±)pindolol on the sensitivity of pre- and postsynaptic Accordingly, preclinical studies have shown that 5-HT1A receptors and terminal 5-HT1B autoreceptors and (±)pindolol can potentiate the enhancing effect of on overall 5-HT neurotransmission. Vol. 25, no 4, 2000 Journal of Psychiatry & Neuroscience 379 Haddjeri and Blier Methods mean of firing rate of neurons from about 1 to 2 minutes before the intravenous administration of the drugs and Male Sprague-Dawley rats (Charles River Laboratories, a mean after, until a plateau was reached. A percentage St-Constant, Que.) weighing 250 to 300 g were kept under change was then calculated. standard laboratory conditions (12-hour light–dark cycle with free access to food and water). Groups of 12 to 22 rats Recordings from CA3 dorsal hippocampus were treated for 2 weeks with (±)pindolol (20 pyramidal neurons mg/kg/day) or vehicle (saline), delivered by osmotic minipumps (ALZA, Palo Alto, Calif.) inserted subcuta- Recording
Load more

Recommended publications
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Antihypertensive Agents Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Antihypertensive Agents Using ALZET Osmotic Pumps 1. Atenolol Q7652: W. B. Zhao, et al. Stimulation of beta-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway. British Journal of Pharmacology 2019;176(14):2465-2481 Agents: Isoproterenol; propranolol; carvedilol; atenolol; ICI-118551 Vehicle: saline; ascorbic acid, buffered; Route: SC; Species: Mice; Pump: 2001; Duration: 1 day; 2 days; 7 days; ALZET Comments: Dose ((ISO 0.6, 6, 20 mg/kg/d), (Prop 2 mg/kg/d), (Carv 2 mg/kg/d), (AT 2 mg/kg/d), (ICI 1 mg/kg/d)); saline with 0.4 mM ascorbic acid used; Controls were non-transgenic and received mp w/ vehicle; animal info (12-16 weeks, Male, (C57BL/6J, beta2-TG, Mst1-TG, or dnMst1-TG)); ICI-118551 is a beta2-antagonist with the structure (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; cardiovascular; Minipumps were removed to allow for washout of ISO overnight prior to imaging; Q7241: M. N. Nguyen, et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep 2018;8(1):8213 Agents: Isoproterenol, Atenolol, ICI-118551 Vehicle: Saline, ascorbic acid; Route: SC; Species: Mice; Pump: Not Stated; Duration: 48 Hours; ALZET Comments: Dose: ISO (2, 6 or 30 mg/kg/day; atenolol (2 mg/kg/day), ICI-118551 (1 mg/kg/day); 0.4 mM ascorbic used; animal info (12 14 week-old C57Bl/6 mice); cardiovascular; Q6161: C.
    [Show full text]
  • Original Article E€Ects of Serotonin 1A Agonist on Acute Spinal Cord Injury
    Spinal Cord (2002) 40, 519 ± 523 ã 2002 International Spinal Cord Society All rights reserved 1362 ± 4393/02 $25.00 www.nature.com/sc Original Article Eects of serotonin 1A agonist on acute spinal cord injury Y Saruhashi*,1, Y Matsusue1 and S Hukuda2 1Department of Orthopedic Surgery, Shiga University of Medical Science, Otsu, Japan; 2Tane-daini Hospital, Osaka, Japan Study design: We evaluated the eects of serotonin (5-HT) agonists on in vitro models of spinal cord compressive injury. Evoked potentials in injured rat spinal cords (n=24) were recorded during perfusion with 5-HT agonists. Objectives: To evaluate the therapeutic eects of 5-HT agonists on the recovery of compound action potentials in injured spinal cords. Methods: Rat dorsal columns were isolated, placed in a chamber, and injured by extradural compression with a clip. Conducting action potentials were activated by supramaximal constant current electrical stimuli and recorded during perfusion with 5-HT agonists and antagonists. Results: After inducing compression injuries, mean action potential amplitudes were reduced to 33.9+5.4% of the pre-injury level. After 120 min of perfusion with Ringer's solution, the mean amplitudes recovered to 62.8+8.4% of the pre-injury level. At a concentration of 100 mM, perfusion with tandospirone (a 5-HT1A agonist) resulted in a signi®cantly greater recovery of mean action potential amplitudes at 2 h after the injury (86.2+6.9% of pre-injury value) as compared with the control Ringer's solution (62.8+8.4% of pre-injury value, P50.05). In contrast, quipazine (a 5-HT2A agonist) accelerated the decrease of amplitude (54.5+11.7% of pre-injury value).
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]
  • 5-HT1A Receptor-Dependent Modulation of Emotional
    www.nature.com/scientificreports OPEN 5-HT1A receptor-dependent modulation of emotional and neurogenic defcits elicited by Received: 8 May 2017 Accepted: 19 January 2018 prolonged consumption of alcohol Published: xx xx xxxx Arnauld Belmer 1,2, Omkar L. Patkar1,2, Vanessa Lanoue3 & Selena E. Bartlett 1,2 Repeated episodes of binge-like alcohol consumption produce anxiety, depression and various deleterious efects including alterations in neurogenesis. While the involvement of the serotonin receptor 1 A (5-HT1A) in the regulation of anxiety-like behavior and neurogenesis is well documented, its contribution to alcohol withdrawal-induced anxiety and alcohol-induced defcits in neurogenesis is less documented. Using the Drinking-In-the-Dark (DID) paradigm to model chronic long-term (12 weeks) binge-like voluntary alcohol consumption in mice, we show that the selective partial activation of 5-HT1A receptors by tandospirone (3 mg/kg) prevents alcohol withdrawal-induced anxiety in a battery of behavioral tests (marble burying, elevated-plus-maze, open-feld), which is accompanied by a robust decrease in binge-like ethanol intake (1 and 3 mg/kg). Furthermore, using triple immunolabelling of proliferation and neuronal diferentiation markers, we show that long-term DID elicits profound defcits in neurogenesis and neuronal fate specifcation in the dorsal hippocampus that are entirely reversed by a 2-week chronic treatment with the 5-HT1A partial agonist tandospirone (3 mg/kg/day). Together, our results confrm previous observations that 5-HT1A receptors play a pivotal role in alcohol drinking behavior and the associated emotional and neurogenic impairments, and suggest that 5-HT1A partial agonists represent a promising treatment strategy for alcohol abuse.
    [Show full text]
  • Antidepressant Potential of Nitrogen-Containing Heterocyclic Moieties: an Updated Review
    Review Article Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review Nadeem Siddiqui, Andalip, Sandhya Bawa, Ruhi Ali, Obaid Afzal, M. Jawaid Akhtar, Bishmillah Azad, Rajiv Kumar Department of ABSTRACT Pharmaceutical Chemistry, Depression is currently the fourth leading cause of disease or disability worldwide. Antidepressant is Faculty of Pharmacy, Jamia Hamdard approved for the treatment of major depression (including paediatric depression), obsessive-compulsive University, Hamdard disorder (in both adult and paediatric populations), bulimia nervosa, panic disorder and premenstrual Nagar, New Delhi - dysphoric disorder. Antidepressant is a psychiatric medication used to alleviate mood disorders, such as 110 062, India major depression and dysthymia and anxiety disorders such as social anxiety disorder. Many drugs produce an antidepressant effect, but restrictions on their use have caused controversy and off-label prescription a Address for correspondence: risk, despite claims of superior efficacy. Our current understanding of its pathogenesis is limited and existing Dr. Sandhya Bawa, E-mail: sandhyabawa761@ treatments are inadequate, providing relief to only a subset of people suffering from depression. Reviews of yahoo.com literature suggest that heterocyclic moieties and their derivatives has proven success in treating depression. Received : 08-02-11 Review completed : 15-02-11 Accepted : 17-02-11 KEY WORDS: Antidepressant, depression, heterocyclic epression is a chronic, recurring and potentially life- monoamine oxidase inhibitors (MAOIs, e.g. Nardil®) tricyclic D threatening illness that affects up to 20% of the population antidepressants (TCAs, e.g. Elavil). They increases the synaptic across the globe.[1] The etiology of the disease is suboptimal concentration of either two (5-HT and NE) or all three (5-HT, concentrations of the monoamine neurotransmitters serotonin NE and dopamine (DA)) neurotransmitters.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • A Systematic Review of the Effectiveness of Antianxiety and Antidepressive Agents for Functional Dyspepsia
    doi: 10.2169/internalmedicine.9099-17 Intern Med 56: 3127-3133, 2017 http://internmed.jp 【 ORIGINAL ARTICLE 】 A Systematic Review of the Effectiveness of Antianxiety and Antidepressive Agents for Functional Dyspepsia Mariko Hojo 1, Akihito Nagahara 2, Daisuke Asaoka 1, Yuji Shimada 2, Hitoshi Sasaki 3, Kohei Matsumoto 1, Tsutomu Takeda 1, Hiroya Ueyama 1, Kenshi Matsumoto 1 and Sumio Watanabe 1 Abstract: Objective Functional dyspepsia (FD) is defined as persistent or recurrent pain or discomfort centered in the upper abdomen without organic disease. Psychosocial factors have been proposed as an important element in the pathophysiology of FD. Therefore, psychotropic agents having antianxiety or antidepressive action are ex- pected to alleviate FD. We previously reported on the treatment of FD using such agents in a systematic re- view, wherein the effectiveness of the agents on FD was suggested, although there were several limitations. We searched for articles on this subject after our systematic review and re-reviewed them systematically. Methods Articles were searched for in MEDLINE from 2003 to 2014 using terms related to antianxiety or antidepressive agents. Clinical studies in which the effectiveness of such agents was clearly stated were se- lected from the retrieved articles. The newly selected and previously selected studies were combined, and sta- tistical analyses were carried out. Results Nine studies were selected. Five of the studies indicated a significant symptomatic improvement us- ing psychotropic drugs. A statistical analysis suggested a significant treatment effect of psychotropic agents having antianxiety or antidepressive action [pooled relative risk (PRR), 0.72; 95% confidence interval (95% CI), 0.52-0.99; p=0.0406] but did not show a significant benefit of treatment with agents having an antide- pressive action alone (PRR, 0.63; 95% CI, 0.38-1.03; p=0.0665).
    [Show full text]